Antibacterial Susceptibility Patterns and Cross-Resistance of Acinetobacter, Isolated from Hospitalized Patients, Southern Iran by Japoni, S et al.
Iranian Red Crescent Medical Journal 
 
Iran Red Crescent Med J 2011; 13(11):832-836 ©Iranian Red Crescent Medical Journal 
SHORT COMMUNICATION
Antibacterial Susceptibility Patterns and Cross-Resistance 
of Acinetobacter, Isolated from Hospitalized Patients, 
Southern Iran 
 
 
S Japoni
1*, S Farshad
2, A Abdi Ali
1,
 A Japoni
2 
 
1Department of Biology, Alzahra University, Tehran, Iran 
2Professor Alborzi Clinical Microbiology   
Research Center, Nemazee hospital, Shiraz University of Medical Sciences, Shiraz, Iran 
 
 
Abstract 
 
Background: Acinetobacter is a multi-drug resistant and nosocomial pathogen. The aim of this study was to 
determine antibacterial susceptibility patterns and cross-resistance of Acinetobacter species. 
 
Methods: This study was conducted in Nemazee Hospital, Shiraz, Iran from October 2007 to September 2008. 
Species identification was carried out by API E20. Minimum inhibitory concentration and cross-resistance of the 
isolated strains to 12 antibiotics were determined by E-test method.  
 
Results: Eighty eight isolates of Acinetobacter were collected from patients’ samples. Acinetobacter baumannii 
was isolated most frequently (79; 89.8%). Colistin, imipenem and meropenem were found to be the three most 
effective antibiotics with 97.7%, 77.3% and 72.7% activity against the isolates, respectively. Multi-drug resistance 
was revealed among 2 to 11 antibiotics and high cross-resistance was also noticed. 
 
Conclusion: To alleviate the situation, strict control measures and appropriate effective antibiotic therapy should 
be adopted to reduce hospital costs and related mortality. 
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Introduction 
 
Acinetobacter is a gram-negative, strictly aerobic, 
non-motile, non-fermentative, oxidase negative, cata-
lase positive and citrate positive bacterium. Most 
strains can grow in a simple mineral medium contain-
ing single carbon and energy source.
1 Acinetobacter 
baumannii is more frequent in clinical samples, while 
A. lwoffii and A. haemolyticus were also isolated in 
environmental settings. Infections due to A. bau-
mannii are frequently found in the intensive care units 
(ICUs), where they are implicated as the cause of 
ventilator-associated pneumonia (VAP), urinary tract 
infections, and bacteremia. In clinical practices, Aci-
netobacter infections are influenced by various risk-
factors including the use of medical devices such as 
endotracheal tubes, intravascular and urinary catheters, 
the exposure to broad-spectrum antibiotics and the ICU 
wards where the patients are admitted and the infection 
rate is high.
2 Resistance rates to fluoroquinolones, 
aminoglycosides, cephalosporins, and penicillins are 
high in several regions. Although carbapenem remains 
mainstay of the therapy for suspected Acinetobacter 
infections, resistance to this antimicrobial class has 
been increasingly reported. Thus, therapeutic options 
can become markedly limited.
3,4 
Major hospital outbreaks, related to multi-drug re-
sistant (MDR) Acinetobacter spp. have been recently 
described in several countries, making surveillance of 
antimicrobial susceptibility an important public health 
task.
5 This study was conducted to assess the preva-
lence of different Acinetobacter species and their cor-
responding frequencies in samples. Furthermore, sus-
ceptibility patterns and cross-resistance of Acineto-
bacter to different antibiotics were determined. 
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Materials and Methods 
 
This study was a cross-sectional one in which bacte-
ria identification was carried out by standard bio-
chemical tests; API E20 (BioMerieux, Marcy I
, 
Etoile, France), in Nemazee Hospital, Shiraz, Iran 
from October 2007 to September 2008. Briefly, the 
isolates which were mostly obtained from blood, 
urine wound and sputum, were sub-cultured on blood 
agar and MacConkey agar to ensure viability and pu-
rity. The isolates were stored at –20ºC in nutrient 
broth containing 50% v/v glycerol. Minimum inhibi-
tory concentration (MIC) of the isolates to 12 antibiot-
ics including ciprofloxacin, colistin, ceftazidime, 
imipenem, ampicillin/sulbactam, meropenem, gentami-
cin, norfloxacin, amikacin, cefepime, tobramycin and 
cefoperazon/sulbactom were determined by E-test 
method and interpreted as recommended by the manu-
facturer's instruction. Cross-resistance of antibiotic re-
sistant isolates to different antibiotics was also evaluat-
ed. 
The data were analyzed statistically by SPSS 
software version 15 (SPSS, Chicago, IL, USA). 
Cross-resistance was obtained by cross tabulation of 
the resistant samples within SPSS software.   
 
 
Results 
 
Eighty eight isolates of Acinetobacter were obtained. 
Acinetobacter spp. was isolated predominantly from 
men (70%), as compared to women (30%). The sam-
ples consist of; 35 (39.8%) blood, 15 (17%) wound, 
15 (17%) sputum, 13 (14.8 %) urine and 10 (11.4%) 
samples of CSF, eyes and joints. Acinetobacter bau-
mannii strains were isolated most frequently (79; 
89.8%), followed by A. lwoffii (8; 9.1%) and A. hae-
molyticus (1; 1.1%). 
Based on the susceptibility  of the isolated Aci-
netobacter to the 12 antibiotics, colistin, imipenem 
and meropenem proved to be the three most effective 
antibiotics with 97.7%, 77.3% and 72.7% activities 
against the isolates, respectively. These data were 
collected in Table 1. Comparison of MICs for the two 
main isolated species revealed that A. baumannii spp. 
was more resistant, compared to A. lwoffii (Table 1). 
Acinetobacter baumannii was resistant between 2 to 
11 antibiotics of which resistance rates of 6, 7 and 8 
antibiotics were observed predominantly (Table 2).To 
more precisely determine the resistance patterns of A. 
baumannii to the tested antibiotics, cross-resistance of 
the isolates was calculated and presented in Table 3.  
High cross-resistance was noticed to the majority of 
the tested antibiotics.  
 
 
Discussion 
 
Various biochemical and molecular methods to iden-
tify  Acinetobacter have been applied. According to 
these methods, these bacteria are categorized into 
Table 1: In vitro susceptibility patterns of 88 Acinetobacter spp. to 12 antibiotics and comparison of susceptibility 
values for A. baumannii and A. lwoffii 
a.
A. lwoffii 
No. 8 
A. baumannii 
No. 79 
Total 
Acinetobacter spp. 
No. 88  Antibiotics 
S (%)  R (%)  S (%)  R (%)  S (%)  R (%) 
8 (100)  0 (0)  9 (11.4)  70 (88.6)  17 (19.3)  71 (80.7)  PM 
6 (75)  2 (25)  10 (12.6)  69 (87.3)  16 (18.2)  72 (81.8)  TZ 
8 (100)  0 (0)  10 (12.6)  69 (87.3)  18 (20.5)  70 (79.5)  GM 
8 (100)  0 (0)  12 (15.2)  67 (84.8)  21 (23.9)  67 (76.1)  NX 
7 (87.5)  1 (12.5)   14 (17.7)  65 (82.3)  22 (25)  66 (75)  AK 
8 (100)  0 (0)  14 (17.7)  65 (82.3)  23 (26.1)  65 (73.9)  CI 
8 (100)  0 (0)  48 (60.7)  31 (39.2)  56 (63.6)  32 (36.4)  TM 
8 (100)  0 (0)  50 (63.3)  29 (36.7)  59 (67)  29 (33)  CPS 
7 (87.5)  1 (12.5)  57 (72.1)  22 (27.8)  54 (61.4)  34 (38.6)  AB 
8 (100)   0 (0)   57 (72.1)  22 (27.8)  64 (72.7)  24 (27.2)  MP 
7 (87.5)  1 (12.5)  61 (77.2)  18 (22.8)  68 (77.3)  20 (22.7)  IP 
8 (100)  0 (0)  78 (98.7)  1 (1.3)  86 (97.7)  2 (2.3)  CO 
a Abbreviations: TZ, ceftazidime; GM, gentamicin; NX, norfloxacin ; AK, amikacin; CI, ciprofloxacin; TM, tobramy-
cin; CPS, cefoperazon/sulbactom AB, ampicillin/sulbactam; MP, meropenem; IP, imipenem; CO, colistin; R, re-
sistant; S, sensitive. Japoni et al. 
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several genomic groups, but only a few have received 
genomic names.
6-8 In this study, 89.8% of the isolates 
were A. baumannii and 10.2% were non-A. baumanni 
(9.1% A. lwoffii and 1.1% A. haemolyticus). Based on 
a study by Feizabadi et al. in Tehran, 84.4% of the 
samples were A. baumannii and 15.6% were non-A. 
Baumannii.
9 Similar to the current results, Seifert et 
al. reported that 72.9% of the clinical specimens were 
A. baumannii and the rest were non-A. Baumannii.
10 
Most samples in the present study were isolated from 
the blood (39.8%) and the rest were isolated from 
wound, sputum, urine and other sites. In Feizabadi et 
al. report, blood samples were more frequent (37.7 
%). Predomination of Acinetobacter from blood sam-
ples may indicate the role of bloodstream in dissemi-
nating the infection.
11  
In the present study, A. baumannii with high re-
sistance to different classes of antibiotics including 
fluoroquinolones, aminoglycosides and cephalo-
sporins were detected. In agreement with this sur-
vey, multi-drug resistant Acinetobacter was isolat-
ed from the hospitalized patients worldwide.
12-17 
Nevertheless, A. lwoffii expressed low resistance to 
the most of tested antibiotics. Low resistance of A. 
lwoffii could be due to the absence of efficient an-
tibiotic resistance capturing system (integron) or as 
a result of its low dissemination in hospital envi-
ronment. It has been proven that A. baumannii has 
infected prolonged hospitalized patients.
18,19  Aci-
netobacter spp. was highly sensitive to colistin 
(97.7%) and moderately sensitive to imipenem 
(77.3%) and meropenem (72.7%). Despite the high 
sensitivity of Acinetobacter  to colistin, its use 
should be restricted to life-threatening conditions 
because of serious neurological and renal side ef-
fects.
20,21 
Table 2: Frequencies and patterns of multi-resistant isolates of Acinetobacter to the tested antibiotics
 a. 
Total No. Antibiotic resistance pattern Resistant 
antibiotics 
12  12  Sensitive  0 
1  1  TZ  1 
4  1 TZ-AK  2 
1  AB-PM 
1  AK-TM 
1  GM-TM 
1  1  AB-IP-MP  3 
2  1  NX-TZ-GM-TM-PM  5 
1  TZ-GM-AK-TM-PM 
17  13  NX-TZ-GM-CI-AK-PM  6 
2  NX-TZ-GM-CI-AB-PM 
1  NX-TZ-GM-AK-TM-PM 
1  NX-TZ-CI-AK-MP-PM 
17  2  NX-TZ-GM-CI-AK-CPS-PM  7 
14  NX-TZ-GM-CI-AK-TM-PM 
1  NX-TZ-GM-CI-AK-PM-CO 
18  1  NX-TZ-GM-AK-IP-TM-MP-PM  8 
11  NX-TZ-GM-CI-AB-AK-CPS-PM 
2  NX-TZ-GM-CI-AK-TM-MP-PM 
1  NX-TZ-GM-CI-AB-AK-TM-PM 
1  TZ-GM-AB-IP-TM-MP-PM-CO 
1  TZ-GM-CI-AK-IP-TM-MP-PM 
1  NX-TZ-GM-CI-AB-AK-TM-MP 
2  2  NX-TZ-GM-CI-AB-IP-CPS-MP-PM  9 
6  6  NX-TZ-GM-CI-AB-AK-IP-CPS-MP-PM  10 
8  8  NX-TZ-GM-CI-AB-AK-IP-TM-CPS-MP-PM  11 
88  88  26 (patterns)  Total 
a Abbreviations: CI, ciprofloxacin; CO, colistin; TZ, ceftazidime: AB, ampicillin/sulbactam; IP, imipenem; MP, 
meropenem; GM, gentamicin; NX, norfloxacin; AK, amikacin: PM, cefepime; TM, tobramycin; CPS, cefopera-
zon/sulbactom Cross-resistance of Acinetobacter 
 
WWW.ircmj.com Vol 13 November 2011  835
The high antibiotic resistance observed in the pre-
sent study, could be due to the extensive clinical ad-
ministration of antibiotics. Acquisition of antibiotic 
resistance in Acinetobacter is a result of transferable 
resistance elements such as plasmid, integron and 
transposon.
22 Of the mentioned factors, integron has 
received more attention in developing antibiotic re-
sistance due to high efficient capturing system.
22-25 To 
alleviate the situation, periodical determination of the 
regional antibiotic susceptibility patterns of Acineto-
bacter is recommended. Furthermore, strict control 
measures and appropriate effective antibiotic therapy 
should be adopted. The majority of the isolated Aci-
netobacter exhibited cross-resistance to the tested 
antibiotics (Table 3), and consequently limited the 
application of effective antibiotics, in cases empiric 
therapy needs to be considered or alternative therapy 
has indication. Determination of the source of infec-
tion in the hospitals using Pulse Field Gel Electropho-
resis (PFGE) and constant training of the medical 
staff to control the infection are also recommended 
and could be helpful. 
 
Conclusion 
 
In conclusion, due to the high possibility of trans-
mission of the antibiotic resistance through a variety 
of transmissible elements such as plasmid, transposon 
and specially integron, reduction in the prevalence of 
multi-drug resistant bacteria in clinics and hospitals is 
mandatory. By taking comprehensive control 
measures and making rational prescription of appro-
priate antibiotics, the situation could be improved 
accordingly to an acceptable level.  
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Table 3: Cross-resistance of Acinetobacter to the tested antibiotics
a.
Number of isolates and percent (value in parenthesis) resistant to  
No. 
 
CO PM MP  CPS  TM IP AK AB CI GM  TZ  NX 
1 
(1.5)
67 
(100)
21 
(31.3) 
29 
(43.3) 
27 
(40.3)
17 
(25.4)
62 
(92.5)
31 
(46.3)
64 
(95.5)
66 
(98.5) 
67 
(100) 
  67  NX 
2 
(2.8) 
70 
(97.2)
23 
(31.9) 
29 
(40.3) 
30 
(41.7) 
19 
(26.4) 
65 
(90.3) 
32 
(44.4) 
65 
(90.3)
69 
(95.8) 
  67 
(93.1) 
72  TZ 
2 
(2.9) 
69 
(98.6)
22 
(31.4) 
29 
(41.4) 
31 
(44.3) 
19 
(27.1) 
63 
(90) 
32 
(45.7) 
64 
(91.4)
  69 
(98.6) 
66 
(94.3) 
70  GM 
1 
(1.5)
65 
(100)
21 
(32.3) 
29 
(44.6) 
25 
(38.5)
17 
(26.2)
61 
(93.8)
31 
(47.7)
  64 
(98.5) 
65 
(100) 
64 
(98.5) 
65  CI 
1 
(2.9) 
33 
(97.1)
19 
(55.9) 
27 
(79.4) 
10 
(29.4) 
18 
(52.9) 
27 
(79.4) 
  31 
(91.2)
32 
(94.2) 
32 
(94.2) 
31 
(91.2) 
34  AB 
1 
(1.5) 
64 
(96.9)
20 
(30.3) 
27 
(40.9) 
29 
(43.90)
16 
(24.2) 
  27 
(40.9) 
61 
(92.4)
63 
(95.4) 
65 
(98.5) 
62 
(93.9) 
66  AK 
1 (5)  19 
(95)
20 
(100) 
16 
(84.2) 
10  
(50)
  16 
(84.2)
18 
(90)
17 
(85)
19 
(95) 
19 
(95) 
17 
(85) 
20  IP 
1 
(3.1) 
30 
(93.7)
13 
(40.6) 
  7 
(21.9) 
  10 
(31.2) 
29 
(90.6) 
10 
(31.2) 
25 
78.1) 
31 
(96.9) 
30 
(93.7) 
27 
(84.4) 
32  TM 
0 (0)  29 
(100) 
16 
(55.2) 
    7 
(24.1) 
16 
(55.2) 
27 
(93.1) 
27 
(93.1) 
29 
(100) 
29 
(100) 
29 
(100) 
29 
(100) 
29  CPS 
1 
(4.2) 
23 
(95.8)
  16 
(66.7) 
13 
(54.2) 
20 
(83.3) 
20 
(83.3) 
19 
(79.2) 
21 
(87.5)
22 
(91.7) 
23 
(95.8) 
21 
(87.5) 
24  MP 
2 
(2.8) 
  23 
(32.4) 
29 
(40.8) 
30 
(42.2) 
19 
(26.8) 
64 
(90.1) 
33 
(46.5) 
65 
(91.5)
69 
(97.2) 
70 
(98.6) 
67 
(94.4) 
71  PM 
  2  
(100) 
1  
(50) 
0  
(0) 
1  
(50) 
1  
(50) 
1  
(50) 
1  
(50) 
1  
(50) 
2 
(100) 
2 
(100) 
1  
(50) 
2  CO 
a Abbreviations: NX, norfloxacin; TZ, ceftazidime ; GM, gentamicin ;CI, ciprofloxacin; AB, ampicillin/sulbactam ;AK, 
amikacin; IP, imipenem; TM, tobramycin ; CPS, cefoperazon/sulbactom ; MP, meropenem;PM, cefepime; CO, col-
istin. 
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